Titlebook: New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere; W. H. Hörl,P. J. Schollmeyer Confere

PLY

书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere影响因子(影响力)




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere影响因子(影响力)学科排名




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere网络公开度




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere网络公开度学科排名




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere被引频次




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere被引频次学科排名




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere年度引用




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere年度引用学科排名




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere读者反馈




书目名称New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere读者反馈学科排名

粉笔

反感

Neutrophil Activation During HemodialysisDialyzing membranes are often used in clinical circumstances and are an important factor in the consideration of biocompatibility with non-biological medical paraphernalia. Depending on the unique physical characteristics of the various filters employed, there are some significant side effects regard to cellular activation.

Libido

Biocompatibility — A System ApproachThe use of more than 2 billion biomaterial devices per year in therapeutic medicine elucidates the magnitude of one of the biggest problems today’s medicine is dealing with. Clinical application of biomaterials has by far exceeded in both quality and quantity our knowledge about the interaction between the biomaterial and the human organism (1).

旁观者

ADJ

Trigger-Point

Treatment of Uraemic Anaemia with Recombinant Human Erythropoietinn deficiency due to blood losses in the extracorporeal circuit (2); severe hyperparathyroidism with osteitis fibrosa (3) ; abnormally high concentrations of aluminium (4). However, there is general agreement that the main cause of uraemic anaemia is the insufficient production of erythropoietin from the diseased kidneys (5).

Initiative

gain631

Is Continuous Haemofiltration Superior to Intermittent Dialysis and Haemofiltration Treatment? to roughly 70% in 1985 (Fig. 1). These figures are drawn from 212 references in the literature assigned to the date of publication or the date at which the publication was received, even where treatment had taken place earlier. Two causes are generally cited for this rise.

平淡而无味